| |
|
|
|
|
|
|
|||
|
Blood, 1 August 2006, Vol. 108, No. 3, pp. 1007-1012. Prepublished online as a Blood First Edition Paper on March 28, 2006; DOI 10.1182/blood-2005-11-4757.
Submitted December 2, 2005
Metabolism Branch, Center for Cancer Research, National Institute of Health, National Cancer Institute, Bethesda, MD, USA * Corresponding author; email: tawald{at}helix.nih.gov.
Adult T-cell leukemia (ATL) consists of an overabundance of T cells, which express CD25. Therapeutic efficacy of astatine-211 labeled murine monoclonal antibody 7G7/B6 alone and in combination with daclizmab was evaluated in NOD/SCID mice injected with MET-1 human T-cell leukemia cells.. 7G7/B6 and daclizmab are directed toward different epitopes of CD25. Either a single dose of 12 µCi 211At-7G7/B6 per mouse given i.v. or receptor saturating doses of daclizmab given at 100 µg weekly for 4 weeks i.v. inhibited tumor growth as monitored by serum levels of human
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||